---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-023899"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:05:21.543343+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics Q1 revenue $56.9M (+96% YoY); first-time positive Adjusted EBITDA $2.5M

## Summary
- Total revenues $56.9M, up 96% YoY; net loss narrowed to $6.8M from $25.0M.
- First-time positive Adjusted EBITDA of $2.5M, ahead of forecast; FY2023 revenue guidance raised to >$220M.
- Gross margin improved to 29.0% from 12.6%; legacy low-margin BIVIGAM inventory nearly depleted.
- ASCENIV production scaled to 4,400L; expects margin expansion and plant capacity improvement.
- Cash $69.2M; working capital $227.4M; strategic review ongoing with Morgan Stanley.

## SEC filing metadata
- accession: 0001140361-23-023899
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/0001140361-23-023899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/brhc20052575_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-023899
- JSON: https://secwatch.observer/filing/0001140361-23-023899.json
- Plain text: https://secwatch.observer/filing/0001140361-23-023899.txt

## Key facts
- Earnings Releases
  ADMA BIOLOGICS, INC. reported first quarter 2023 results: revenue $57 Million, net income Net Loss of $6.8 Million.
  - Period: first quarter 2023
  - Revenue: $57 Million
  - Net income: Net Loss of $6.8 Million
  - Result: reported results
  source text: 1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/0001140361-23-023899-index.htm
- Earnings Releases
  ADMA BIOLOGICS, INC. reported FY2023 results: revenue $220 Million. Guidance raised.
  - Period: FY2023
  - Revenue: $220 Million
  - Guidance: raised
  - Result: guidance update
  source text: FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased from $210 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/0001140361-23-023899-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.